

ITM, CIRC promote medical radioisotopes in China

November 20, 2019 | News

Sign Technology License Agreement for the Production and Distribution of Medical Radioisotopes



Germany based ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and Chengdu Gaotong Isotope Co., Ltd. a subsidiary of China Isotope & Radiation Corporation (CIRC), a nuclear technology application products manufacturer and supplier, have announced that they have signed a technology license agreement for the production and distribution of ITM Germanium-68/Gallium-68 Generators and no-carrier-added (n.c.a) Lutetium-177 (EndolucinBeta®) in China.

ITM and CIRC have already been working together in a successful partnership for almost 10 years in which CIRC has distributed ITM's medical radioisotopes, generators and equipment to the Chinese market. China's radiopharmaceutical market is now growing rapidly in line with the fast expanding clinical evidence and use of Targeted Radionuclide Therapies worldwide.

In order to meet the rising demand for Targeted Radionuclide Therapy in China, ITM and CIRC have decided to enter into a technology license agreement. Under the terms of the agreement, CIRC's subsidiary Gaotong will implement the production of $^{68}\text{Ge}/^{68}\text{Ga}$ Generators and n.c.a. Lutetium-177 (EndolucinBeta®), in China for the Chinese market, as well as joining ITM's global network of OEM suppliers in support of ITM's international framework agreements with strategic partners. Additional terms of the agreement are not disclosed.

The global ITM OEM Network serves the worldwide radiopharmaceutical market with OEM partners in the US, Australia and South Africa providing security of supply and scalability of medical radioisotopes for the exponentially growing use of Theranostics in Precision Oncology. With this new partnership, CIRC is now the fourth partner to join the global ITM OEM Processing and Production Network.